Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer.

##STR00001##

The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabolic syndrome component conditions.

##STR00001##

This invention relates to compounds of formula 1, 2 or 3 ##STR00001##
a pharmaceutically acceptable salt, or solvate thereof, wherein X.sub.1, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as defined herein. The compounds are antimicrobial agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1, 2 or 3.

This invention relates to compounds of formula 1, 2 or 3 ##STR00001##
a pharmaceutically acceptable salt, or solvate thereof, wherein X.sub.1, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are as defined herein. The compounds are antimicrobial agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1, 2 or 3.

The present disclosure compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the TEAD transcription factor, and are useful in the treatment of diseases related to the activity of TEAD transcription factor including, e.g., cancer and other diseases.

The subject matter disclosed herein is directed to novel She inhibitors of Formula (II). These compounds are useful for treating impaired insulin sensitivity, glucose tolerance, obesity, diabetes, metabolic syndrome, NAFLD, NASH, PSC, PBC, or other metabolic syndrome component conditions. ##STR00001##

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.

##STR00001##

A polycyclic compound according to an embodiment of the inventive concept is represented by the following Formula 1:

##STR00001##

In Formula 1, Ar.sub.1 and Ar.sub.2 are each independently substituted or unsubstituted aryl group having 6 to 30 carbon atoms for forming a ring, or substituted or unsubstituted heteroaryl group having 2 to 30 carbon atoms for forming a ring, where Ar.sub.1 and Ar.sub.2 may combine with each other to form a ring, and A is represented by the following Formula 2-1 or 2-2:

##STR00002##

The present invention provides to an improved process for the preparation of highly pure Erlotinib hydrochloride of formula (I)

##STR00001##

The substantially pure Erlotinib hydrochloride (I) obtained by improved process of the present invention is having purity of greater than 99.8% (% w/w by HPLC).
Erlotinib hydrochloride is useful in the treatment of cancer more particularly in the treatment of lung cancer and pancreatic cancer.

The present invention provides to an improved process for the preparation of highly pure Erlotinib hydrochloride of formula (I)

##STR00001##

The substantially pure Erlotinib hydrochloride (I) obtained by improved process of the present invention is having purity of greater than 99.8% (% w/w by HPLC).
Erlotinib hydrochloride is useful in the treatment of cancer more particularly in the treatment of lung cancer and pancreatic cancer.